Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
10/16/2024 | $22.00 | Outperform → Strong Buy | Raymond James |
9/27/2024 | $10.00 → $13.00 | Overweight | JP Morgan |
9/19/2024 | $11.00 | Buy | B. Riley Securities |
9/9/2024 | $10.00 | Overweight | JP Morgan |
5/15/2024 | $11.00 | Overweight | Wells Fargo |
12/19/2023 | $5.00 → $12.00 | Market Perform → Outperform | Leerink Partners |
7/5/2023 | $7.00 | Outperform | Raymond James |
5/24/2023 | $7.00 → $5.00 | Buy → Hold | Jefferies |
8-K - Wave Life Sciences Ltd. (0001631574) (Filer)
8-K - Wave Life Sciences Ltd. (0001631574) (Filer)
8-K - Wave Life Sciences Ltd. (0001631574) (Filer)
Raymond James upgraded Wave Life Sciences from Outperform to Strong Buy and set a new price target of $22.00
JP Morgan resumed coverage of Wave Life Sciences with a rating of Overweight and set a new price target of $13.00 from $10.00 previously
B. Riley Securities initiated coverage of Wave Life Sciences with a rating of Buy and set a new price target of $11.00
4 - Wave Life Sciences Ltd. (0001631574) (Issuer)
4 - Wave Life Sciences Ltd. (0001631574) (Issuer)
4/A - Wave Life Sciences Ltd. (0001631574) (Issuer)
4 - Wave Life Sciences Ltd. (0001631574) (Issuer)
4 - Wave Life Sciences Ltd. (0001631574) (Issuer)
4 - Wave Life Sciences Ltd. (0001631574) (Issuer)
CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Tuesday, November 12, 2024, to review the company's third quarter 2024 financial results and provide business updates. The webcast and conference call may be accessed by visiting "Investor Events" on the investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Analysts planning to participate during the Q&A portion of the live call can join the conference
WVE-007 (INHBE GalNAc-siRNA for obesity) is on track to initiate a clinical trial in 1Q 2025; new preclinical data for WVE-007 demonstrate opportunities for monotherapy, for synergistic use with GLP-1s, and for maintenance to avoid rebound weight gain following cessation of GLP-1s Recent proof-of-mechanism data for WVE-006 unlocked Wave's best-in-class RNA editing capabilities; three new wholly owned RNA editing programs targeting PNPLA3, LDLR and APOB are first-in-class approaches to address significant unmet needs in cardiometabolic diseases Wave plans to have five GalNAc-RNA editing or GalNAc-siRNA programs in the clinic by 2026 Wave's clinically validated platform continues to l
Achieved proof-of-mechanism for Wave's RNA editing platform; restoring levels of wild-type (edited) M-AAT that are consistent with the heterozygous "MZ" genotype with low risk of AATD lung and liver disease A single subcutaneous dose of WVE-006 in the first two patients with homozygous "ZZ" AATD resulted in mean plasma total AAT levels of ~11 micromolar, with mean wild-type M-AAT representing more than 60% of total AAT; durable editing with M-AAT protein observed through 57 days Wave expects to share multidose data from the RestorAATion-2 trial in 2025 Annual Research Day on October 30th will highlight WVE-006 proof-of-mechanism data and Wave's new wholly owned GalNAc-RNA editing pr
SC 13D/A - Wave Life Sciences Ltd. (0001631574) (Subject)
SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)
SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)
CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of Erik Ingelsson, MD, PhD, as Chief Scientific Officer. Dr. Ingelsson will drive Wave's emerging therapeutic portfolio strategy, including growing its genetics and genomics capabilities for identifying new, high impact targets, and leveraging the company's best-in-class multimodal discovery and development platform to advance transformative RNA medicines. Most recently, Dr. Ingelsson served as Senior Vice President, Head of Target Discovery, at GSK
BOTHELL, Wash., March 21, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Michael A. Panzara, M.D., MPH to its Board of Directors. Dr. Panzara currently serves as Chief Medical Officer, Head of Therapeutics Discovery and Development at Wave Life Sciences (NASDAQ:WVE) and brings over 20 years of biopharmaceutical industry experience developing therapies for neurological disorders, including in leadership roles at Sanofi Genzyme and Biogen. "Mike is a recognized and experienced leader in the development
CAMBRIDGE, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Jonathan Rosin has been appointed as Chief Human Resources Officer (CHRO). As CHRO, Mr. Rosin will provide strategic enterprise counsel and leadership, both as a member of Wave’s Executive Team and by leading the human resources function. “Jonathan is an accomplished leader with the breadth of human resources experience necessary to help guide Wave as we prepare to support five programs in clinical trials in 2021, as well as advance a robust precl
CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Tuesday, November 12, 2024, to review the company's third quarter 2024 financial results and provide business updates. The webcast and conference call may be accessed by visiting "Investor Events" on the investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Analysts planning to participate during the Q&A portion of the live call can join the conference
Mean muscle content-adjusted dystrophin expression of 9.0% and unadjusted dystrophin of 5.5%, with high consistency across participants, in a prespecified analysis; dystrophin was comprised of two isoforms consistent with Becker muscular dystrophy patients who display milder disease Data demonstrated meaningful improvement in serum biomarkers for muscle health, with localization of WVE-N531 in myogenic stem cells and regeneration of myofibers Skeletal muscle concentrations of ~41,000 ng/g combined with 61-day tissue half-life support monthly dosing going forward; preclinical data suggest participants may have even higher concentrations in heart and diaphragm WVE-N531 was safe and well tol
Successful clinical translation of Wave's RNA medicines platform in HD patients with WVE-003 provides further validation of Wave's proprietary platform with PN and stereochemistry; opt-in package for WVE-003 submitted to partner Takeda and engagement with regulators initiated to discuss potential path to accelerated approval Dystrophin data on track for 3Q 2024 from potentially registrational FORWARD-53 trial of WVE-N531, which has previously demonstrated industry-leading exon skipping of 53%; positive data would unlock a best-in-class functional dystrophin franchise for DMD Dosing initiated in 3Q 2024 in RestorAATion-2 clinical trial of WVE-006 in AATD patients; proof-of-mechanism da
During the last three months, 4 analysts shared their evaluations of WAVE Life Sciences (NASDAQ:WVE), revealing diverse outlooks from bullish to bearish. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 1 0 0 0 2M Ago 0 1 0 0 0 3M Ago 1 0 0 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $15.5, a high estimate of $19.00, and a low estimate of $11.00. Observing a dow
HC Wainwright & Co. analyst Andrew Fein reiterates WAVE Life Sciences (NASDAQ:WVE) with a Buy and maintains $15 price target.
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 0.2% on Wednesday. Shares of Worthington Enterprises, Inc. (NYSE:WOR) fell sharply in today's pre-market trading after the company posted downbeat quarterly results. Worthington Industries posted adjusted earnings of 74 cents per share, missing analysts' estimates of 94 cents per share. The company posted quarterly sales of $318.801 million versus estimates of $359.390 million, according to data from Benzinga Pro. Worthington shares dipped 7.5% to $46.38 in pre-market trading. Here are some big stocks recording losses in today's pre-market trading session. Taysha Gene Therapies, Inc. (NASDAQ:TS